查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971041

抗肥胖藥物市場－全球產業規模、佔有率、趨勢、機會與預測：按作用機制、藥物類型、地區和競爭格局分類，2021-2031年

Anti-Obesity Drugs Market - Global Industry Size, Share, trends, Opportunity, and Forecast, Segmented By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs), By Drug Type (Prescription Drugs, OTC Drugs), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球抗肥胖藥物市場預計將從 2025 年的 32.1 億美元成長到 2031 年的 80.4 億美元，複合年成長率為 16.54%。

該領域涵蓋旨在透過調節食慾、影響代謝和促進營養吸收等機制來促進體重減輕和維持的藥物製劑。受慢性體重相關疾病的增加以及藥物療法在治療第2型糖尿病等合併症方面日益普及的推動，該市場呈現穩定成長的態勢。世界肥胖聯盟（WOF）預測，到2030年，全球成年人肥胖人口將達到11.3億，反映了有效醫療介入的迫切性。

市場概覽
預測期 2027-2031
市場規模：2025年 32.1億美元
市場規模：2031年 80.4億美元
複合年成長率：2026-2031年 16.54%
成長最快的細分市場 處方藥
最大的市場 北美洲

然而，市場擴張的主要障礙在於新療法的高成本以及許多地區保險報銷體系的不完全。這些經濟障礙往往使患者無法獲得長期治療方案，從而可能延緩先進體重管理方案的普及，尤其是在低收入者身上。

市場促進因素

全球肥胖和超重人口的成長是推動市場擴張的主要動力，亟需治療性介入來減輕公共衛生負擔。日益嚴重的代謝危機刺激了人們對藥物解決方案的需求，以應對嚴重的體重相關併發症，並將醫療保健的重點轉向健康管理，以預防危及生命的疾病。根據世界肥胖聯盟於2025年3月發布的《2025年世界肥胖地圖集》，超重和肥胖每年導致約160萬人死於非傳染性疾病，凸顯了對有效藥物治療的迫切需求。

同時，基於腸促胰素療法的顯著臨床療效和商業性成功正在改變這一領域。這些療法在調節食慾和代謝功能方面樹立了新的治療標準，生物製藥顯著的減重效果也證明了藥物治療在體重管理方面的有效性。因此，處方量激增，帶動了強勁的收入成長。為了應對這項商業性成功，競爭對手正在加速開發下一代促效劑。根據諾和諾德公司於2025年2月發布的2024會計年度年度報告，其肥胖症治療產品的銷售額成長了57%，達到651億丹麥克朗。此外，Fierce Pharma在2024年12月的一篇報導中報道稱，該公司將額外投資29億丹麥克朗，以擴大品管能力。

市場挑戰

新型抗肥胖藥物價格高昂（通常每年超過數千美元）以及保險政策的限制，大大阻礙了市場的快速擴張。健康保險公司和支付方擔心藥物廣泛使用所帶來的經濟負擔，因此實施了嚴格的准入機制，例如複雜的預先核准要求和嚴格的BMI基準值。這種報銷環境造成了臨床需求與商業性准入之間的巨大差距，實際上將大規模一部分合格醫療條件但無力承擔自付費用的患者排除在外，並將藥物的使用限制在富裕人群中。

根據管理式醫療藥房學院（Managed Care Pharmacy Academy）2025年發布的行業數據，平均而言，只有31%的商業保險用戶享有抗肥胖藥物的醫保，而支付方則將預算大幅增加視為擴大醫保覆蓋範圍的主要障礙。這種有限的健保覆蓋迫使絕大多數潛在患者自行承擔高昂的費用，直接導致銷售量下降，並阻礙了市場充分發揮其收入潛力。這些經濟壁壘使得只有極小一部分潛在市場能夠獲得藥物，嚴重阻礙了全球抗肥胖藥物產業的成長。

市場趨勢

隨著製藥公司努力克服單一促效劑療法的臨床局限性，提高耐受性和療效的聯合療法的研發正在推動市場發展。製藥公司正增加作用機制互補的藥物的使用，例如將GLP-1類似物和Amylin類似物聯合使用，旨在協同改善代謝結果並減重不利事件，最終目標是達到與減肥手術相當的減重效果。例如，2024年12月，諾和諾德宣布，其在研的固定劑量複方製劑Caglisema（卡格列肽和Semaglutide的組合藥物）在REDEFINE 1試驗中，經過68週的治療，患者減重顯著減輕了22.7%，遠優於單藥治療。

同時，口服小分子製劑的出現正在重塑這一領域。這解決了注射用生物製藥在規模化生產和用藥依從性方面面臨的挑戰。與需要複雜低溫運輸物流的胜肽類注射劑不同，小分子藥物可以更經濟高效地生產，並以方便的每日片劑形式給藥。這有望提高患者的用藥可近性和依從性。這些製劑的研發正在快速開發平臺，為長期體重管理提供了一種非侵入性選擇。 2024年11月，Viking Therapeutics公司報告稱，接受最高劑量口服片劑VK2735治療的患者，在短短28天的治療後，平均體重減輕高達8.2%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球抗肥胖藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 作用機轉（周邊作用藥物、中樞作用藥物）
    • 藥物類型（處方藥、非處方藥）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美抗肥胖藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲抗肥胖藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區抗肥胖藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲抗肥胖藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲抗肥胖藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球抗肥胖藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Alizyme PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Currax Pharmaceuticals LLC
  • Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Pfizer Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24055

The Global Anti-Obesity Drugs Market is projected to expand from USD 3.21 Billion in 2025 to USD 8.04 Billion by 2031, registering a CAGR of 16.54%. This sector comprises pharmaceutical formulations aimed at facilitating weight reduction and maintenance through mechanisms such as appetite regulation, metabolic influence, or nutrient absorption. The market is experiencing robust growth fueled by the rising prevalence of chronic weight-related disorders and the increasing acceptance of pharmacotherapy as a treatment for comorbidities like type 2 diabetes. Highlighting the urgency for effective medical interventions, updated projections from the World Obesity Federation in 2025 estimate that the global number of adults living with obesity will rise to 1.13 billion by 2030.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.21 Billion
Market Size 2031USD 8.04 Billion
CAGR 2026-203116.54%
Fastest Growing SegmentPrescription Drugs
Largest MarketNorth America

However, a significant obstacle to broader market expansion is the high cost of novel therapeutics coupled with inadequate insurance reimbursement policies in many regions. These financial barriers frequently restrict patient access to long-term treatment regimens and may slow the adoption of advanced weight management solutions, particularly among lower-income populations.

Market Driver

The escalating global prevalence of obesity and overweight populations serves as the primary catalyst for market expansion, creating an urgent need for therapeutic interventions to alleviate public health burdens. This deepening metabolic crisis is driving demand for pharmaceutical solutions that address severe weight-related complications, shifting healthcare priorities toward medical management to prevent life-threatening conditions. According to the World Obesity Federation's 'World Obesity Atlas 2025', released in March 2025, overweight and obesity are responsible for approximately 1.6 million premature deaths annually from non-communicable diseases, underscoring the imperative for effective pharmacological treatments.

Concurrently, the sector has been transformed by the high clinical efficacy and commercial success of incretin-based therapies, which have established a new standard of care for regulating appetite and metabolic function. The substantial weight loss outcomes achieved by these biologics have validated pharmacotherapy for weight management, resulting in surging prescription volumes and robust revenue growth. This commercial viability is prompting competitors to accelerate the development of next-generation agonists. As noted in Novo Nordisk's 'Annual Report 2024' from February 2025, sales of its Obesity Care products rose by 57 percent to DKK 65.1 billion, while a December 2024 Fierce Pharma article reported that the company committed an additional DKK 2.9 billion to expand its quality control capabilities in Denmark.

Market Challenge

The rapid acceleration of the market is severely hindered by the high cost of novel anti-obesity medications, which often exceed thousands of dollars annually, combined with restrictive insurance policies. Health insurers and payers, wary of the financial strain associated with widespread utilization, have implemented stringent gatekeeping measures such as complex prior authorization requirements and strict body mass index thresholds. This reimbursement landscape creates a significant disconnect between clinical demand and commercial access, effectively excluding a large demographic of patients who are medically eligible but financially unable to afford out-of-pocket expenses, thereby limiting adoption primarily to affluent populations.

According to industry data cited by the Academy of Managed Care Pharmacy in 2025, only 31% of commercial plan members on average possessed coverage for anti-obesity medications, with payers citing high budget impacts as the primary barrier to broader reimbursement. This limited coverage forces the majority of potential patients to face prohibitive costs alone, directly reducing sales volume and preventing the market from reaching its full revenue potential. By restricting access to a fraction of the total addressable market, these financial barriers significantly curtail the growth trajectory of the global anti-obesity sector.

Market Trends

A dominant market force is the development of combination therapies designed to enhance tolerability and efficacy, as developers strive to surpass the clinical ceilings of mono-agonist treatments. Pharmaceutical companies are increasingly co-formulating agents with complementary mechanisms of action, such as GLP-1 analogues combined with amylin analogues, to synergistically improve metabolic outcomes and mitigate adverse events, aiming for weight loss results that rival bariatric surgery. For instance, Novo Nordisk announced in December 2024 that CagriSema, an investigational fixed-dose combination of cagrilintide and semaglutide, achieved a superior weight loss of 22.7% after 68 weeks in the REDEFINE 1 trial, significantly outperforming individual monotherapies.

Simultaneously, the sector is being reshaped by a transition toward oral small molecule formulations, which address the scalability and compliance limitations of injectable biologics. Unlike peptide-based injectables that require complex cold-chain logistics, small molecule drugs can be manufactured more cost-effectively and administered as convenient daily pills, potentially broadening patient access and adherence. This formulation evolution is rapidly advancing through clinical pipelines, offering a non-invasive alternative for long-term weight management. In November 2024, Viking Therapeutics reported that patients receiving the highest dose of its oral tablet formulation, VK2735, achieved a mean body weight reduction of up to 8.2% after just 28 days of treatment.

Key Market Players

  • Alizyme PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Currax Pharmaceuticals LLC
  • Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Pfizer Inc

Report Scope

In this report, the Global Anti-Obesity Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Obesity Drugs Market, By Mechanism

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Anti-Obesity Drugs Market, By Drug Type

  • Prescription Drugs
  • OTC Drugs

Anti-Obesity Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Obesity Drugs Market.

Available Customizations:

Global Anti-Obesity Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Obesity Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs)
    • 5.2.2. By Drug Type (Prescription Drugs, OTC Drugs)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Anti-Obesity Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Mechanism
    • 6.2.2. By Drug Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anti-Obesity Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Mechanism
        • 6.3.1.2.2. By Drug Type
    • 6.3.2. Canada Anti-Obesity Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Mechanism
        • 6.3.2.2.2. By Drug Type
    • 6.3.3. Mexico Anti-Obesity Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Mechanism
        • 6.3.3.2.2. By Drug Type

7. Europe Anti-Obesity Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Mechanism
    • 7.2.2. By Drug Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anti-Obesity Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Mechanism
        • 7.3.1.2.2. By Drug Type
    • 7.3.2. France Anti-Obesity Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Mechanism
        • 7.3.2.2.2. By Drug Type
    • 7.3.3. United Kingdom Anti-Obesity Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Mechanism
        • 7.3.3.2.2. By Drug Type
    • 7.3.4. Italy Anti-Obesity Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Mechanism
        • 7.3.4.2.2. By Drug Type
    • 7.3.5. Spain Anti-Obesity Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Mechanism
        • 7.3.5.2.2. By Drug Type

8. Asia Pacific Anti-Obesity Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Mechanism
    • 8.2.2. By Drug Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anti-Obesity Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Mechanism
        • 8.3.1.2.2. By Drug Type
    • 8.3.2. India Anti-Obesity Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Mechanism
        • 8.3.2.2.2. By Drug Type
    • 8.3.3. Japan Anti-Obesity Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Mechanism
        • 8.3.3.2.2. By Drug Type
    • 8.3.4. South Korea Anti-Obesity Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Mechanism
        • 8.3.4.2.2. By Drug Type
    • 8.3.5. Australia Anti-Obesity Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Mechanism
        • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Anti-Obesity Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Mechanism
    • 9.2.2. By Drug Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anti-Obesity Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Mechanism
        • 9.3.1.2.2. By Drug Type
    • 9.3.2. UAE Anti-Obesity Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Mechanism
        • 9.3.2.2.2. By Drug Type
    • 9.3.3. South Africa Anti-Obesity Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Mechanism
        • 9.3.3.2.2. By Drug Type

10. South America Anti-Obesity Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Mechanism
    • 10.2.2. By Drug Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anti-Obesity Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Mechanism
        • 10.3.1.2.2. By Drug Type
    • 10.3.2. Colombia Anti-Obesity Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Mechanism
        • 10.3.2.2.2. By Drug Type
    • 10.3.3. Argentina Anti-Obesity Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Mechanism
        • 10.3.3.2.2. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anti-Obesity Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Alizyme PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bayer AG
  • 15.3. Bristol-Myers Squibb Co
  • 15.4. Currax Pharmaceuticals LLC
  • 15.5. Hoffmann-La Roche AG
  • 15.6. GlaxoSmithKline PLC
  • 15.7. Merck & Co. Inc.
  • 15.8. Norgine BV
  • 15.9. Novo Nordisk AS
  • 15.10. Pfizer Inc

16. Strategic Recommendations

17. About Us & Disclaimer